These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2447997)

  • 21. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy.
    Grignon D; Troster M
    Prostate; 1985; 7(2):195-202. PubMed ID: 2413432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma.
    Matzkin H; Soloway MS
    Urology; 1992 Jul; 40(1):78-80. PubMed ID: 1377847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice.
    Daver A; Soret JY; Coblentz Y; Allain YM; Cellier P; Chauveau P
    Am J Clin Oncol; 1988; 11 Suppl 2():S53-60. PubMed ID: 2468273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
    Turkes A; Nott J; Turkes AO; Griffiths K
    Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour markers in prostatic cancer.
    Cooper EH
    Scand J Clin Lab Invest Suppl; 1991; 206():42-51. PubMed ID: 1719610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material.
    Shah NT; Tuttle SE; Strobel SL; Gandhi L
    J Surg Oncol; 1985 Aug; 29(4):265-8. PubMed ID: 2417056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
    Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
    Wang TY; Kawaguchi TP
    Ann Clin Lab Sci; 1986; 16(6):461-6. PubMed ID: 3800301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
    Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
    Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
    Citrin DL; Resnick MI; Guinan P; al-Bussam N; Scott M; Gau TC; Kennealey GT
    Prostate; 1991; 18(2):139-46. PubMed ID: 1826048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared.
    Schifman RB; Ahmann FR; Elvick A; Ahmann M; Coulis K; Brawer MK
    Clin Chem; 1987 Nov; 33(11):2086-8. PubMed ID: 2445507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
    Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
    JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE
    Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract]   [Full Text] [Related]  

  • 38. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
    Siddall JK; Hetherington JW; Cooper EH; Newling DW; Robinson MR; Richards B; Denis L
    Br J Urol; 1986 Dec; 58(6):676-82. PubMed ID: 2432985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
    Bauer HW
    Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
    Fosså SD; Waehre H; Paus E
    Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.